fluoxetine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   70 Trials   70 Trials   3689 News 


«12...7071727374757677787980...8182»
  • ||||||||||  fluoxetine / generics
    Biomarker, Preclinical, Journal:  Protective effect of Convolvulus pluricaulis against neuroinflammation associated depressive behavior induced by chronic unpredictable mild stress in rat. (Pubmed Central) -  Apr 3, 2019   
    ...A consecutive one-week treatment of CPE (50, and 100 mg/kg) or fluoxetine (10 mg/kg, p.o.) treatment significantly increased sucrose preference index, reduced immobility time in the FST, and increased the number of squares crossed, the number of rearing in the OFT and locomotion in the actophotometer in the CUMS-exposed rats...However, CPE (25 mg/kg) exerted insignificant protection against CUMS-induced depressive-like behavior and associated neuroinflammation. Therefore, this study demonstrates that CPE exerted antidepressant-like effect which could be mediated by anti-inflammatory potential, restoring liver biomarkers or monoaminergic responses in the stressed rats.
  • ||||||||||  fluoxetine / generics
    Journal:  Extracellular Regulated Protein Kinaseis critical for the role of 5-HT1a receptor in modulating nNOS expression and anxiety-related behaviors. (Pubmed Central) -  Mar 30, 2019   
    Our previous study found that serotonin 1A receptor (5-HT1aR) is an endogenous suppressor of nNOS expression in the hippocampus, which accounts for anxiolytic effect of fluoxetine...By using 8-OH-DPAT, a selective 5-HT1aR agonist, NAN-190, a selective 5-HT1aR antagonist, and U0126, an Extracellular Regulated Protein Kinases (ERK) phosphorylation inhibitor, we investigated the role of ERK in 5-HT1aR-nNOS pathway...Besides, our data showed that ERK phosphorylation was essential for 5-HT1aR activation-induced cAMP responsive element binding protein (CREB) phosphorylation, hippocampal neurogenesis and synaptogenesis of newborn neuron. Our study suggests a crucial role of ERK phosphorylation in the regulation of nNOS expression by 5-HT1aR, which is helpful for understanding the mechanism of 5-HT1aR-based anxiolytic treatment.
  • ||||||||||  fluoxetine / generics
    Journal:  Protecting the environment from psychoactive drugs: Problems for regulators illustrated by the possible effects of tramadol on fish behaviour. (Pubmed Central) -  Mar 30, 2019   
    ...The positive control drug, the anti-depressant fluoxetine, produced the expected exposed fish explored the novel tank more, and swam more slowly while doing so...The relevance of these findings may apply much more widely than just the environmental risk assessment of psychoactive drugs. They suggest that much more rigorous training of research scientists and regulators is probably required if consensus decisions are to be reached that adequately protect the environment from chemicals.
  • ||||||||||  fluoxetine / generics
    Journal:  Ion channel and neurotransmitter modulators as electroceutical approaches to the control of cancer. (Pubmed Central) -  Mar 29, 2019   
    ...To support this methodology, we present new data on the effects of the SSRI Prozac and its analog (ZINC ID = ZINC06811610) on survival of both cancer (MCF7) and normal (MCF10A) breast cells exposed to these compounds...This constitutes a proof-of-concept demonstration for our hypothesis that the use of both existing and novel drugs as electroceuticals could serve as an alternative to highly toxic chemotherapy strategies replacing or augmenting them with less toxic alternatives. We believe this new approach forms an exciting roadmap for future biomedical advances.
  • ||||||||||  fluoxetine / generics
    Journal:  Does fluoxetine improve recovery after stroke? (Pubmed Central) -  Mar 28, 2019   
    Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. Lancet 2019;393:256-74.The study was funded by the UK Stroke Association and the NIHR Health Technology Assessment Programme project number 13/04/30.To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000729/a-commonly-used-antidepressant-doesnt-improve-recovery-after-stroke.
  • ||||||||||  citalopram / generics, paroxetine / generics, fluoxetine / generics
    Preclinical, Journal:  Mouse strain differences in SSRI sensitivity correlate with serotonin transporter binding and function. (Pubmed Central) -  Mar 27, 2019   
    Paroxetine similarly reduced immobility time in both strains...These results suggest that immobility duration depends on 5-HT transporter binding levels, which lead to apparent strain differences in immobility time in the FST and TST. Furthermore, differences in 5-HT transporter binding may cause variations in SSRI effects on behaviors.
  • ||||||||||  fluoxetine / Generic mfg.
    Enrollment open, Trial completion date, Trial primary completion date:  FLOW: Fluoxetine Opens Window to Improve Motor Recovery After Stroke (clinicaltrials.gov) -  Mar 26, 2019   
    P2,  N=176, Recruiting, 
    Furthermore, differences in 5-HT transporter binding may cause variations in SSRI effects on behaviors. Not yet recruiting --> Recruiting | Trial completion date: Dec 2020 --> Sep 2020 | Trial primary completion date: Dec 2020 --> Sep 2020
  • ||||||||||  fluoxetine / generics
    Preclinical, Journal:  Body composition, biochemical, behavioral and molecular alterations in overfed rats after chronic exposure to SSRI. (Pubmed Central) -  Mar 25, 2019   
    ...Fluoxetine (FLX), a selective serotonin reuptake inhibitor (SSRI) that increases 5-HT availability in the synaptic cleft may thus have potential effects on energy balance...Results showed that FLX induced reductions in several murinometric indices, improvement of adipose profile, hypophagic behavior, reduction in serum parameters, and positive modulation of hypophagia-related genes. These data suggest that the beneficial effects of FLX-treatment on overfeeding-induced physical and behavioral effects in rats was due to hypothalamic alterations that led to improvement in energy balance in animals with a compromised metabolism.
  • ||||||||||  venlafaxine / generics, amitriptyline / generics, fluoxetine / generics
    Review, Journal:  Antidepressants for Preventive Treatment of Migraine. (Pubmed Central) -  Mar 22, 2019   
    SSRIs including fluoxetine are not effective for most patients...Antidepressants are an important option for preventive treatment of migraine. Further research on the efficacy and tolerability of SNRIs as migraine preventives is needed.
  • ||||||||||  fluoxetine / Generic mfg.
    Trial completion, Trial completion date:  Randomized Clinical Trial of a Mindfulness Based Intervention in Generalized Anxiety Disorder (clinicaltrials.gov) -  Feb 27, 2019   
    P=N/A,  N=200, Completed, 
    Therefore the new image analysis system presented here was proven to be sensitive and versatile enough to detect changes in diel vertical migration across light intensities and low concentration levels of neuro-active drugs. Enrolling by invitation --> Completed | Trial completion date: Dec 2019 --> Dec 2018
  • ||||||||||  fluoxetine / Generic mfg.
    Trial primary completion date:  EFFECTS: Efficacy of Fluoxetine - a Trial in Stroke (clinicaltrials.gov) -  Feb 27, 2019   
    P3,  N=1500, Recruiting, 
    Enrolling by invitation --> Completed | Trial completion date: Dec 2019 --> Dec 2018 Trial primary completion date: Jul 2019 --> Dec 2019
  • ||||||||||  aripiprazole / Generic mfg., fluoxetine / Generic mfg.
    Trial completion date, Trial primary completion date:  Fluoxetine vs Aripiprazole Comparative Trial (FACT) (clinicaltrials.gov) -  Feb 20, 2019   
    P4,  N=48, Recruiting, 
    Trial primary completion date: Jul 2019 --> Dec 2019 Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019
  • ||||||||||  fluoxetine / Generic mfg.
    Trial completion date, Trial primary completion date, HEOR:  Comparison of Acupuncture and Fluoxetine on Quality of Life in Menopausal Women (clinicaltrials.gov) -  Feb 16, 2019   
    P=N/A,  N=140, Enrolling by invitation, 
    Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Feb 2019
  • ||||||||||  fluoxetine / Generic mfg.
    New P1 trial:  Poststroke Depression in Hemorrhagic Stroke (clinicaltrials.gov) -  Feb 1, 2019   
    P1,  N=224, Not yet recruiting, 
  • ||||||||||  fluoxetine / Generic mfg.
    Trial completion date, Trial primary completion date:  Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM) (clinicaltrials.gov) -  Jan 31, 2019   
    P1,  N=64, Recruiting, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Oct 2018 --> Feb 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  Fetzima (levomilnacipran ER) / Pierre Fabre, AbbVie
    Trial completion date, Trial primary completion date:  Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder (clinicaltrials.gov) -  Jan 24, 2019   
    P3,  N=660, Recruiting, 
    Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Dec 2018 --> Dec 2019
  • ||||||||||  fluoxetine / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  Effects rTMS Combined With Fluoxetine on Motor Recovery in Stroke Patients (clinicaltrials.gov) -  Oct 25, 2018   
    P2,  N=45, Active, not recruiting, 
    Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Nov 2018 --> Nov 2019 Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Jun 2019 | Trial primary completion date: Jun 2018 --> Jun 2019
  • ||||||||||  fluoxetine / Generic mfg.
    Enrollment change, Trial withdrawal:  Fluoxetine Prevention Trial (clinicaltrials.gov) -  Oct 15, 2018   
    P1,  N=0, Withdrawn, 
    Recruiting --> Completed N=376 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  fluoxetine / Generic mfg.
    Trial initiation date:  FLOW: Fluoxetine Opens Window to Improve Motor Recovery After Stroke (clinicaltrials.gov) -  Oct 11, 2018   
    P2,  N=176, Not yet recruiting, 
    N=376 --> 0 | Not yet recruiting --> Withdrawn Initiation date: Jun 2018 --> Nov 2018
  • ||||||||||  fluoxetine / Generic mfg.
    Trial completion date, Trial primary completion date:  Pharmaco(Epi)Genetic Study of Obsessive-Compulsive Disorder (clinicaltrials.gov) -  Sep 7, 2018   
    P=N/A,  N=200, Recruiting, 
    Not yet recruiting --> Recruiting | N=165 --> 300 Trial completion date: Jun 2019 --> Dec 2023 | Trial primary completion date: Dec 2018 --> Dec 2023
  • ||||||||||  bupropion sustained-release / Generic mfg., fluoxetine / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Bupropion for Depression in ESRD Patients on Hemodialysis (clinicaltrials.gov) -  Jul 17, 2018   
    P4,  N=1, Terminated, 
    Recruiting --> Enrolling by invitation N=40 --> 1 | Trial completion date: Dec 2018 --> Mar 2018 | Recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Mar 2018; Study stopped due to difficulty recruiting
  • ||||||||||  Trial completion date, Trial primary completion date:  The Gut Microbiota in Obsessive-Compulsive Disorder (clinicaltrials.gov) -  Apr 11, 2018   
    P=N/A,  N=25, Recruiting, 
    Trial completion date: Oct 2018 --> May 2021 | Trial primary completion date: Oct 2018 --> May 2021 Trial completion date: Mar 2018 --> Mar 2020 | Trial primary completion date: Dec 2017 --> Dec 2019